Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria,
J Cancer Res Clin Oncol. 2013 Oct;139(10):1771-5. doi: 10.1007/s00432-013-1475-4. Epub 2013 Jul 20.
The management of patients with mantle cell lymphoma (MCL) not eligible for stem cell transplantation in relapse after receiving standard approaches remains challenging, and the search for active and tolerable regimens is still warranted.
We have retrospectively analyzed activity of rituximab (375 mg/m(2) i.v. day 1), Ara-C (1,000 mg i.v. total twice daily on day 2) and oxaliplatin (130 mg/m(2) i.v. day 3) (R-ADOx) in 12 patients (median age 69 years) with relapsed MCL.
Patients had been heavily pretreated (median 3 prior therapies, range 1-9) and had stage III/IV disease. Nine out of 12 patients responded (75 %, 4 CR, 5 PR). Median progression-free survival was 9.3 months, and overall survival has not been reached. Adverse events greater than grade II included anemia (17 %) and thrombocytopenia (33 %).
R-ADOx is active and well tolerated in heavily pretreated MCL patients.
对于不符合干细胞移植条件的复发套细胞淋巴瘤 (MCL) 患者，在接受标准治疗后，其管理仍然具有挑战性，因此仍需要寻找有效且耐受良好的治疗方案。
我们回顾性分析了利妥昔单抗（375mg/m²，静脉注射，第 1 天）、阿糖胞苷（1000mg，静脉注射，总量 2 次/天，第 2 天）和奥沙利铂（130mg/m²，静脉注射，第 3 天）（R-ADOx）在 12 例复发 MCL 患者（中位年龄 69 岁）中的疗效。
患者先前接受了大量治疗（中位 3 次治疗，范围 1-9 次），且处于 III/IV 期疾病。12 例患者中有 9 例（75%，4 例完全缓解，5 例部分缓解）有反应。中位无进展生存期为 9.3 个月，总生存期尚未达到。大于 2 级的不良事件包括贫血（17%）和血小板减少症（33%）。
R-ADOx 在既往大量治疗的 MCL 患者中具有活性且耐受性良好。
